Discover
SVRA
Savara Inc.
6.06
2 x 4.52
2 x 7.74
bid
ask
-
0.10
1.62%
2 @ 05:14 AM
5.96 -0.10 (1.65%)
| Ytd | 0.50% | |
| 1y | 188.57% |
6.00
day range
6.29
2.03
52 week range
7.00
| Open | 6.13 | Prev Close | 6.16 | Low | 6.00 | High | 6.29 | Mkt Cap | 1.24B |
| Vol | 1.50M | Avg Vol | 1.56M | EPS | -0.56 | P/E | N/A | Forward P/E | -20.61 |
| Beta | 0.27 | Short Ratio | 19.82 | Inst. Own | 104.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 5.28 | 200-d Avg | 5.17 | 1yr Est | 10.94 |
SVRA News
fool.com
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted ave
benzinga.com
Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; CO
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare